OnKommon · Precision oncology intelligence

Every cancer is different.

Understand the cancer. Connect the evidence. Follow what changes — with OnKommon Twin, built on a proprietary 21-layer analytical architecture and led by the treating oncologist.

Explore Twin Choose your path

01 · Inside one cell

Cancer begins inside a cell.

Molecular testing reads what has changed in a tumour's DNA and RNA — within what each test covers.

02 · The genome

Inside each tumour, the genome changes.

Some changes may drive growth. Many are background. Some remain unresolved. Telling them apart is where interpretation begins.

03 · The evidence

The evidence lives in pieces.

Molecular & genomic · Tumour biology · Clinical context · Imaging integration · Immune landscape · Treatment exposure · Patient factors · Evidence ecosystem — arriving separately, and changing over time.

04 · Our core technology

OnKommon Twin brings it together.

A proprietary 21-layer analytical architecture — five groups of layers, each asking a defined scientific question, read into one structured view for the treating oncologist.

Go inside every layer

OnKommon

Understand the cancer. Follow what changes.

A model of the available information — reviewed as new evidence arrives, and led by the treating oncologist.

Choose your storyline

One core. Six storylines.

OnKommon serves patients, doctors, hospitals, laboratories, industry and research. Choose yours — you can switch at any time from the bar at the top of every page, or open the journey map.

Longitudinal intelligence

OnKommon Twin

A living model of the cancer journey: four testing pathways, 21 proprietary analytical layers, longitudinal and track monitoring — in one clinician-led view.

Explore Twin

Exploratory research

OnKommon AVATAR

A biological investigational plan: whole-exome interpretation with mutation-informed fruit-fly modelling and candidate-drug screening.

Explore AVATAR

The Twin lifecycle · 01 · Sample

It begins with a sample.

Blood, bone marrow or tumour tissue — depending on the testing pathway the treating team chooses.

02 · Sequencing

The sample is sequenced.

Sequencing reads the tumour's DNA — and RNA where the pathway includes it — and the molecular findings are identified.

03 · Data informs the layers

The data flows into the 21 layers.

Molecular findings join clinical context, imaging, treatment history and the evidence in Twin's proprietary 21-layer architecture.

04 · Day 0

The Twin is created.

The baseline is established from the available information — and what is missing is recorded.

05 · Longitudinal monitoring

Every change goes in.

Platelets, LFT and IHC panels, scans, symptoms and treatment changes — shared by the patient or care team by upload or on WhatsApp — are added to the Twin as they happen.

06 · Symptom mapping

A new symptom is mapped.

When the clinical picture changes — a new symptom, result or scan — the change is mapped onto the Twin and connected to the evidence.

07 · The model updates

And the model updates.

Dynamic Twin Updates refresh the model so the picture reflects what has changed. New evidence can prompt reassessment.

08 · Track monitoring

A genetic read, every three months.

Twin tracks are OnKommon's genetic tracking tests — each with its own designed panel, ranges and integrated biomarkers. Track 12, 47 or 118 keeps the Twin alive across a journey of up to 12 years.

09 · Over the years

The Twin evolves with the patient.

Every update is reviewed and signed by the treating oncologist — who decides what comes next.

06 · The model

Amodeloftheavailableinformation—notacopyofthepatient.Reviewedasnewevidencearrives.Itinforms;itneverdecides.

07 · A separate offering · OnKommon AVATAR

A genomic findingis a starting point.

AVATAR pairs genomic interpretation with investigational, mutation-informed Drosophila modelling and candidate-drug screening for solid-tumour research.

01Interpret
02Model
03Screen
04Review

Research useAVATAR findings are investigational: a response in the fruit-fly model is not proof of efficacy in a patient.

Explore AVATAR research Step through the stages

08 · The decision

The treating oncologistdecides.

OnKommon organises the evidence. Every Twin report is reviewed and signed by the treating oncologist, then taken to KPCIRC's Molecular Tumour Board — and the oncologist owns every decision. “The Clinical Twin belongs to the treating oncologist and their patient.”

The KPCIRC sign-off process

A gold fountain pen resting on a white surface.

Structured report

Treating oncologistReviewed & signed

Evidence and governance

Show the evidence behind every claim

Accredited & compliant

CAP-accredited
NABL-accredited
ISO-certified
HIPAA-compliant
GDPR-compliant

Explore how OnKommon Twin connects the cancer journey.

Request a professional demonstration, or build a Twin yourself.

Build a Twin Request a demonstration